Why focal cartilage damage in the knee rarely heals on its own

Damaged knee cartilage presents a straightforward biological problem: it cannot repair itself the way bone or soft tissue can. Articular cartilage — the smooth, load-bearing surface lining the knee joint — has no direct blood supply. Without that supply, the inflammatory signals and stem-cell recruitment that normally begin any healing response simply never arrive. A scratch on skin heals; a scratch on cartilage does not.

This matters most when the damage is focal — a discrete, contained area of full-thickness cartilage loss (classified as ICRS grade III or IV) rather than the diffuse, widespread wear of osteoarthritis. Focal chondral defects are most commonly caused by injury, a single impact to the joint, or repetitive loading in younger, active people. Because the surrounding cartilage may still be healthy, restoration rather than joint replacement is a realistic goal — but only if the defect is treated deliberately.

Left unaddressed, even a small focal defect can enlarge over time, gradually eroding the surrounding tissue and accelerating compartmental arthritis. The urgency is greatest in patients who are younger or place high demands on the joint. Choosing the right repair strategy depends on several factors — defect size, depth, its precise location on the knee, and the condition of the bone immediately beneath it — which is why two quite different surgical approaches have been developed to address this problem.

What each procedure actually involves

The clearest way to understand the choice between these two procedures is to follow what happens to the patient from surgery to recovery.

AMIC: one operation, one anaesthetic

In AMIC (Autologous Matrix-Induced Chondrogenesis), everything takes place in a single sitting. The surgeon first performs microfracture — making small channels through the floor of the cartilage defect into the underlying bone. This releases a blood clot rich in mesenchymal stem cells from the bone marrow. A bilayer collagen membrane (most commonly Chondro-Gide®, a type I/III porcine collagen scaffold) is then cut to the precise shape of the defect and fixed over the clot in the same operation, stabilising it and creating a biological environment that guides the stem cells towards cartilage-like tissue. The patient leaves hospital having had one procedure and faces a single rehabilitation course. AMIC developed as a direct augmentation of microfracture, specifically to address the durability problems — significant score deterioration between 18 and 36 months — seen with microfracture performed alone.

MACI: biopsy, laboratory, second surgery

MACI (Matrix-Induced Autologous Chondrocyte Implantation) is unavoidably two-stage. At the first, arthroscopic visit, a small sliver of healthy cartilage is harvested from a non-weight-bearing area of the knee. That biopsy is sent to a specialist laboratory, where the patient's own chondrocytes are expanded over approximately four to six weeks and seeded uniformly onto a collagen membrane of the same type used in AMIC. A second operation then implants this cell-laden membrane into the defect. MACI itself evolved from first-generation ACI, where cells were held in place by a periosteal patch; seeding them directly onto the membrane simplified the technique without removing the two-stage requirement. In August 2024, an arthroscopic delivery option — MACI Arthro — received FDA approval for patients aged 18–55, making the reimplantation step less invasive for suitable candidates, but the preceding biopsy and cell-culture phase remain unchanged.

The two procedures share the same scaffold material; what distinguishes them is the biological source of the repair cells — marrow-derived stem cells recruited on the day in AMIC, versus cultured autologous chondrocytes grown over weeks in MACI.

Defect size: the clearest triage rule

Size, more than any other single variable, determines which procedure belongs on the table.

For defects smaller than roughly 2 cm², neither AMIC nor MACI is typically the first call. At that scale, microfracture alone or mosaicplasty (osteochondral autograft transfer) generally suffices, and the complexity of either membrane-based technique is difficult to justify.

AMIC occupies the middle ground: it is most consistently reported for defects in the 2–8 cm² range. Registry data from Gille et al. (57 patients) place the mean treated area at 3.4 cm² — a useful benchmark for the typical AMIC candidate.

Once defects grow larger, or when multiple lesions are present, the marrow clot that AMIC relies on becomes the limiting factor. A bone marrow blood clot supplies a finite and uncontrolled number of mesenchymal progenitor cells; it cannot scale with defect area the way laboratory culture can. This is the biological logic behind steering larger defects — broadly above approximately 4 cm², or multifocal — towards MACI: weeks of cell culture generates a substantially greater volume of chondrocytes that can be seeded uniformly across the membrane before reimplantation.

The SUMMIT randomised trial provided direct evidence for this threshold, demonstrating that MACI produced superior KOOS pain and function scores compared with microfracture at both 2 and 5 years in patients with defects of 3 cm² or more.

That said, the 2–4 cm² band is genuinely contested territory. Defect size alone does not cleanly resolve the decision there — which is addressed in the section that follows.

Other factors surgeons weigh when size alone does not decide

Age and activity demands are often the first secondary consideration. MACI tends to be favoured for younger, high-demand patients — particularly athletes with larger lesions where the priority is durable hyaline-like repair tissue capable of tolerating high-impact loading over many years. For an older patient with a lesion in the contested 2–4 cm² range and more modest activity goals, the additional complexity of a two-stage procedure is harder to justify on clinical grounds alone.

Subchondral bone integrity matters in a more technical sense. AMIC's biological mechanism depends on an adequate marrow signal through the subchondral plate. Where that plate is already damaged — by previous microfracture, bone cysts, or sclerosis — the marrow response may be insufficient to populate the scaffold, and a cell-seeded implant such as MACI, which delivers chondrocytes independently of marrow access, may offer a more reliable substrate.

Joint alignment introduces a staging question. Some surgeons combine AMIC with a high tibial osteotomy in a single operative episode, correcting mechanical load-sharing and addressing the cartilage lesion together. Incorporating MACI's two-stage protocol into the same sequence is more complex to coordinate and may not be practical in every centre.

The two-operation burden of MACI is a genuine consideration for patients with comorbidities, demanding work schedules, or caring responsibilities — two separate anaesthetics and a four-to-six-week laboratory interval represent a meaningful logistical and physical commitment. AMIC is also considerably less resource-intensive: it does not require specialist cell-therapy laboratory infrastructure, making it more widely accessible and lower in direct cost.

Where a lesion genuinely sits in the overlap zone, surgeon experience and centre volume legitimately shape the decision — and that is a reasonable reflection of how specialised cartilage surgery works rather than a gap in the evidence.

What the head-to-head evidence shows

Direct head-to-head data comparing AMIC and MACI are limited, which shapes how the existing studies should be interpreted.

The most widely cited comparison is Migliorini et al.'s 2022 systematic review in the British Medical Bulletin, which found AMIC outperforming MACI at approximately 40 months of follow-up, with notably lower complication rates in the AMIC group. That result is counterintuitive given MACI's status as the preferred approach for larger defects — and the most plausible explanation is selection bias. AMIC series predominantly include smaller lesions, and smaller lesions tend to do better regardless of technique. Reading the Migliorini finding as evidence that AMIC is categorically superior would overclaim what the data support.

Schneider et al.'s 2025 retrospective matched-pair study (n=48, treated 2016–2021, published in PMC) offers a more controlled picture, comparing AMIC, MACI, and a third technique — MCI (Matrix-induced Chondrogenesis) — side by side. As one matched-pair series rather than a randomised trial, it provides the most direct current comparison, not a definitive verdict.

At the level of individual outcome improvement, the evidence is reasonably consistent: AMIC produces approximately a 4-point reduction in VAS pain scores across pooled data; MACI shows durable gains in pain and function extending to 10 years with low reoperation rates. Both techniques work.

What the evidence has not yet provided is a long-term RCT in which patients with genuinely matched defect sizes are randomised between the two. Most AMIC data come from registries and shorter-follow-up case series, and the influence of subchondral bone status on comparative outcomes is not consistently captured. For patients currently deciding, that means the size-based triage described in the preceding sections — combined with individual clinical assessment — remains the most reliable guide available.

Recovery timelines and what to ask before choosing

Committing to either procedure means committing to a recovery measured in months, not weeks — and understanding that timeline before surgery is part of making a sound decision.

MACI carries a longer total treatment period. The laboratory phase adds four to six weeks between biopsy and implantation, and return to heavy sport or high-impact activity after the second operation typically takes nine to twelve months as the cultured chondrocytes mature and integrate. AMIC follows a broadly comparable post-operative arc, though recovery varies with defect size and whether concurrent procedures — such as an osteotomy — are performed at the same time. Surgeon-specific guidance is essential here; general timelines are a starting point, not a guarantee.

Before a cartilage consultation, it is worth arriving with a handful of direct questions: How large is my defect, and what grade does imaging suggest? Does it fall clearly in the AMIC window, the MACI window, or the overlap zone where either might be reasonable? Is my subchondral bone healthy enough to support a marrow-based repair? What are this centre's caseload and reported outcomes for each technique?

MRI assessment — including T2 mapping and cartilage segmentation — can define defect depth, size, and subchondral bone status with enough precision to anchor that planning conversation before any surgical decision is finalised.

Neither AMIC nor MACI is a standard NHS pathway, and access varies across the country. A consultant-led private assessment can clarify which route is appropriate without a long wait. Lincolnshire Knee is part of the MSK Doctors group and accepts patients without a GP referral — lincolnshireknee.co.uk.